In transcriptomics, sample quality often dictates experimental success. When working with ultra-low input samples, you rarely have the luxury of a “perfect” starting material.

If you work with clinical biobanks or archived human tissues, you know that Formalin-Fixed, Paraffin-Embedded (FFPE) tissue blocks are a scientific goldmine. They hold decades of patient history, treatment outcomes, and clinical endpoints.

When your entire experiment relies on a few hundred laser-captured cells, a rare circulating tumor cell population, or a handful of precious fluorescence-activated cell sorting (FACS) isolates, the stakes at the laboratory bench are exceptionally high.

When designing a transcriptomics experiment, researchers focus deeply on biological variables: choosing the right time points, establishing robust controls, and ensuring sufficient biological replicates.

Every molecular biologist knows the unique anxiety of submitting samples for next-generation sequencing. You have spent weeks, perhaps months, culturing cells, dosing animal models, or meticulously microdissecting tissues.

Gynecological cancers, including ovarian, cervical, uterine, and endometrial cancers, remain some of the most complex malignancies to study. While survival has improved in many cancers, uterine corpus cancer is trending upward; in 2025, the U.S. is expected to see 69,120 new cases and 13,860 deaths, and mortality increased about 1.5% per year from 2013 to 2022. These trends point to the need for deeper molecular data to guide translational research.